Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Non-Current Deffered Revenue data on record, last reported at $206.0 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 12.15% year-over-year to $206.0 million; the TTM value through Dec 2025 reached $206.0 million, down 12.15%, while the annual FY2025 figure was $206.0 million, 12.15% down from the prior year.
  • Non-Current Deffered Revenue reached $206.0 million in Q4 2025 per FHTX's latest filing, up from $193.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $322.7 million in Q4 2021 and bottomed at $1.9 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $228.3 million, with a median of $262.8 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 16324.84% in 2022, then fell 22.62% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $322.7 million in 2021, then fell by 5.8% to $304.0 million in 2022, then decreased by 11.8% to $268.1 million in 2023, then fell by 12.55% to $234.5 million in 2024, then dropped by 12.15% to $206.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $206.0 million in Q4 2025, $193.1 million in Q3 2025, and $206.8 million in Q2 2025.